The authors reply.

Tytuł:: The authors reply.
Autorzy:: Plata-Menchaca EP; Shock, Organ Dysfunction, and Resuscitation (SODIR) Research Group, Vall d'Hebron Research Institute, Vall d´Hebron Barcelona Hospital Campus, Barcelona, Spain.
Ferrer R; Shock, Organ Dysfunction, and Resuscitation (SODIR) Research Group, Vall d'Hebron Research Institute, Vall d´Hebron Barcelona Hospital Campus, Barcelona, Spain.; Intensive Care Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias, Barcelona, Spain.
Źródło:: Critical care medicine [Crit Care Med] 2021 Jun 01; Vol. 49 (6), pp. e660-e661.
Typ publikacji:: Research Support, Non-U.S. Gov't; Letter; Comment
Język:: English
Imprint Name(s):: Publication: Philadelphia, PA : Lippincott Williams & Wilkins
Original Publication: New York, Kolen.
References:: Honore PM, Redant S, Kaefer K, et al. Procalcitonin Is Useful for Antibiotic De-Escalation in Sepsis and Septic Shock: Beware of Some Confounders! Crit Care Med. 2021; 49:e659.
Plata-Menchaca EP, Ferrer R. Procalcitonin is useful for antibiotic deescalation in sepsis. Crit Care Med. 2021; 49:693–696.
Ceccarelli G, Alessandri F, Sargentini V, et al. Impact of continuous renal replacement therapy (CRRT) and other extracorporeal support techniques on procalcitonin guided antibiotic therapy in critically ill patients with septic shock. Clin Chem Lab Med. 2019; 57:e86–e87.
Level C, Chauveau P, Guisset O, et al. Mass transfer, clearance and plasma concentration of procalcitonin during continuous venovenous hemofiltration in patients with septic shock and acute oliguric renal failure. Crit Care. 2003; 7:R160–R166.
Dahaba AA, Elawady GA, Rehak PH, et al. Procalcitonin and proinflammatory cytokine clearance during continuous venovenous haemofiltration in septic patients. Anaesth Intensive Care. 2002; 30:269–274.
Lorton F, Veinberg F, Ielsch D, et al. Procalcitonin serum levels in children undergoing chronic haemodialysis. Pediatr Nephrol. 2007; 22:430–435.
Entry Date(s):: Date Created: 20210520 Date Completed: 20210902 Latest Revision: 20210902
Update Code:: 20240104
DOI:: 10.1097/CCM.0000000000004997
PMID:: 34011842
: Raport

Competing Interests: Dr. Ferrer received funding from Thermofisher and Biomereux. Dr. Plata-Menchaca has disclosed that she does not have any potential conflicts of interest.

Comment on: Crit Care Med. 2021 Apr 1;49(4):693-696. (PMID: 33315698)
Comment on: Crit Care Med. 2021 Jun 1;49(6):e659. (PMID: 34011841)

Informacja